Prospective Grant of Exclusive License: Diagnostics of Fungal Infections, 33905 [05-11512]

Download as PDF Federal Register / Vol. 70, No. 111 / Friday, June 10, 2005 / Notices Thursday, May 12, 2005, Volume 70, Number 91, pages 25075–25079. The notice is amended as follows: Page 25076, first column, Letter of Intent Deadline, delete June 13, 2005, and replace with August 15, 2005. Page 25076, first column, Application Deadline, delete June 27, 2005, and replace with August 31, 2005. Page 25076, third column, Fiscal Year Funds, delete 2005, and replace with 2006. Page 25076, third column, Anticipated Award Date, delete August 31, 2005, and replace with November 30, 2005. Page 25077, third column, LOI Deadline Date, delete June 13, 2005, and replace with August 15, 2005. Page 25077, third column, Application Deadline Date, delete June 27, 2005, and replace with August 31, 2005. Page 25079, first column, Award Date, delete August 31, 2005, and replace with November 30, 2005. Dated: June 2, 2005. William P. Nichols, Director, Procurement and Grants Office, Centers for Disease Control and Prevention. [FR Doc. 05–11524 Filed 6–9–05; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Exclusive License: Diagnostics of Fungal Infections Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services. ACTION: Notice. AGENCY: SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent application referred to below to AerovectRx (AVRX), Corporation having a place of business in Norcross, Georgia. The patent rights in these inventions have been assigned to the government of the United States of America. The patent applications to be licensed are: PCT/US02/7973 entitled ‘‘Systems and Methods for Aerosol Delivery of Agents,’’ filed 03.13.2002; and, PCT/US03/019684 entitled ‘‘Mixing Vial,’’ filed 06.20.2003. VerDate jul<14>2003 17:22 Jun 09, 2005 Jkt 205001 Status: Pending. Issue Date: N/A. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Technology: This technology adds a new way to deliver vaccines, specifically in mass immunization campaigns. Requests for a copy of this patent application, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, telephone: (770) 488–8610; facsimile: (770) 488–8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A Signed Confidential Disclosure Agreement (available under Forms at https://www.cdc.gov/tto) will be required to receive a copy of any pending patent application. ADDRESSES: Dated: June 1, 2005. James D. Seligman Associate Director for Program Services, Centers for Disease Control and Prevention. [FR Doc. 05–11512 Filed 6–9–05; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families [Program Announce No. ‘‘HHS–2005–ACF– OCS–EI–0053; CFDA 93.602] Office of Community Services Announcement for Assets for Independence Program Grants Office of Community Services (OCS), Administration for Children and Families, U.S. Department of Health and Human Services. ACTION: Notice of availability. AGENCY: Notice of an amendment to the announcement published on February 9, 2005, concerning the application process for Assets for Independence PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 33905 Program grants. This document announces an additional closing date of July 15, 2005. It also announces two informational telephone conference calls about the Assets for Independence Program and the process for submitting a grant proposal. The program announcement concerning the application process for Assets for Independence Program grants published on February 9, 2005 in Volume 70, Federal Register, pages 6879–6888 is hereby modified. The announcement is modified by adding one additional application due date of July 15, 2005, and a notification of two informational telephone conference calls concerning the Assets for Independence Program and the process for submitting a grant proposal. SUMMARY: On February 9, 2005, the Office of Community Services, Administration for Children and Families, U.S. Department of Health and Human Services published an announcement seeking applications for the Assets for Independence Program. The announcement appeared in Volume 70, pages 6879–6888 of the Federal Register. This document announces one additional application due date of July 15, 2005, which is in addition to the three due dates listed in the February 9 standing announcement (March 15, June 15 and November 1). To be considered timely for this additional due date only, applications must be received at the OCS Operations Center by July 15. (For more details, see submission dates and times section below.) This document also announces two informational telephone conference calls concerning the Assets for Independence Program and the process for submitting a grant application. Submission Dates and Times: The new additional closing date for the Assets for Independence Program is July 15, 2005. (This closing date is in addition to three other valid closing dates—March 15, June 15 and November 1—as noted in the current standing announcement.) Applications received after 4:30 p.m. eastern time on the July 15 closing date will be classified as late, and will not be reviewed this cycle. Deadline: Applications shall be considered as meeting an announced deadline if they are received on or before the due date. Applicants are responsible for ensuring applications are mailed or submitted electronically well in advance of the application due date. Applications hand carried by applicants, applicant couriers, other representatives of the applicant, or by overnight/express mail couriers shall be E:\FR\FM\10JNN1.SGM 10JNN1

Agencies

[Federal Register Volume 70, Number 111 (Friday, June 10, 2005)]
[Notices]
[Page 33905]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-11512]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Diagnostics of Fungal 
Infections

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, limited 
field of use, exclusive license to practice the inventions embodied in 
the patent application referred to below to AerovectRx (AVRX), 
Corporation having a place of business in Norcross, Georgia. The patent 
rights in these inventions have been assigned to the government of the 
United States of America. The patent applications to be licensed are:

PCT/US02/7973 entitled ``Systems and Methods for Aerosol Delivery of 
Agents,'' filed 03.13.2002; and,
PCT/US03/019684 entitled ``Mixing Vial,'' filed 06.20.2003.

    Status: Pending.
    Issue Date: N/A.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    Technology: This technology adds a new way to deliver vaccines, 
specifically in mass immunization campaigns.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within sixty days of this notice will 
be considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A Signed Confidential Disclosure 
Agreement (available under Forms at https://www.cdc.gov/tto) will be 
required to receive a copy of any pending patent application.

    Dated: June 1, 2005.
James D. Seligman
Associate Director for Program Services, Centers for Disease Control 
and Prevention.
[FR Doc. 05-11512 Filed 6-9-05; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.